It is well established that treatment with TZD, a PPARG agonist in T2DM, leads to PPARG activation and causes enhanced insulin sensitivity, resulting in decreased plasma insulin and glucose levels [69]. Here, PPARG is linked to type 2 diabetes mellitus.